EyePoint Pharmaceuticals Inc.

NAS: EYPT

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

EyePoint Pharmaceuticals Inc.

After Hours

--Quotes are delayed by 20 min

May 26, 2023, 7:57 p.m.

EYPT

/zigman2/quotes/210537129/composite

5.96

Change

+0.03 +0.51%

Volume

Volume 9,866

Quotes are delayed by 20 min

/zigman2/quotes/210537129/composite

Previous close

$ 5.93

Change

0.00 0.00%

Day low

Day high

$5.76

$6.10

52 week low

52 week high

$2.19

$11.44

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for EyePoint Pharmaceuticals Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	5.86M	20.37M	34.44M	36.94M	41.4M
Sales Growth	-	247.76%	69.10%	7.27%	12.09%
Cost of Goods Sold (COGS) incl. D&A	-	5.15M	8.28M	10.64M	10.38M
COGS excluding D&A	-	2.54M	5.64M	7.87M	7.93M
Depreciation & Amortization Expense	2.65M	2.6M	2.65M	2.77M	2.45M
Depreciation	194,000	144,000	189,000	311,000	396,000
Amortization of Intangibles	2.46M	2.46M	2.46M	2.46M	2.05M
COGS Growth	-	-	60.95%	28.40%	-2.45%
Gross Income	-	15.22M	26.15M	26.3M	31.03M
Gross Income Growth	-	-	71.86%	0.57%	17.97%
Gross Profit Margin	-	-	-	-	74.94%	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	52.32M	63.08M	63.44M	81.58M	109.97M
Research & Development	20.82M	15.37M	17.42M	28.5M	49.64M
Other SG&A	31.5M	47.71M	46.02M	53.08M	60.32M
SGA Growth	-	20.56%	0.58%	28.58%	34.80%
Other Operating Expense	-	-	-	-	-
Unusual Expense	18.89M	3.81M	905,000	(2.07M)	22.26M
EBIT after Unusual Expense	(68M)	(51.67M)	(38.2M)	(53.21M)	(101.2M)
Non Operating Income/Expense	(18.89M)	-	-	-	-
Non-Operating Interest Income	734,000	1.05M	58,000	292,000	2.13M
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	3.28M	6.18M	7.26M	5.5M	3.19M
Interest Expense Growth	-	88.06%	17.50%	-24.24%	-42.00%
Gross Interest Expense	3.28M	6.18M	7.26M	5.5M	3.19M
Interest Capitalized	-	-	-	-	-
Pretax Income	(89.44M)	(56.79M)	(45.39M)	(58.42M)	(102.25M)
Pretax Income Growth	-	36.50%	20.07%	-28.69%	-75.04%
Pretax Margin	-	-	-	-	-246.97%	NA
Income Tax	-	-	-	-	-
Income Tax - Current Domestic	-	-	-	-	-
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(89.44M)	(56.79M)	(45.39M)	(58.42M)	(102.25M)
Minority Interest Expense	-	-	-	-	-
Net Income	(89.44M)	(56.79M)	(45.39M)	(58.42M)	(102.25M)
Net Income Growth	-	36.50%	20.07%	-28.69%	-75.04%
Net Margin Growth	-	-	-	-	-246.97%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(89.44M)	(56.79M)	(45.39M)	(58.42M)	(102.25M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(89.44M)	(56.79M)	(45.39M)	(58.42M)	(102.25M)
EPS (Basic)	(10.50)	(5.44)	(3.54)	(2.03)	(2.74)
EPS (Basic) Growth	-	48.14%	35.05%	42.56%	-34.90%
Basic Shares Outstanding	8.51M	10.43M	12.84M	28.76M	37.32M
EPS (Diluted)	(10.50)	(5.44)	(3.54)	(2.03)	(2.74)
EPS (Diluted) Growth	-	48.14%	35.05%	42.56%	-34.90%
Diluted Shares Outstanding	8.51M	10.43M	12.84M	28.76M	37.32M
EBITDA	(46.47M)	(45.26M)	(34.64M)	(52.51M)	(76.49M)
EBITDA Growth	-	2.60%	23.46%	-51.57%	-45.69%
EBITDA Margin	-	-	-	-	-184.75%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

EyePoint Pharmaceuticals Inc.

Annual Financials for EyePoint Pharmaceuticals Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk